Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Burger

Showing results (781-790 of 1,123) with videos related to

Pageof 113
Sort By:
Antiviral Therapy|October 2, 2003
Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavirRob E Aarnoutse, Jan-Christian Wasmuth, Gerd Fätkenheuer, et al.
Der Urologe. Ausg. A|July 2, 2016
[What do prostate cancer patients know about smoking? : Results of a bicentric questionnaire study (KRAUT study)]M May, C Gilfrich, P Spachmann, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysisN de Rouw, S Croes, R Posthuma, et al.
Antiviral Therapy|February 7, 2009
Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once dailyMichiel van der Flier, Gwenda Verweel, Linda C van der Knaap, et al.
Atherosclerosis|August 10, 2024
Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trialsPascal M Burger, Jannick A N Dorresteijn, Stefan Koudstaal, et al.
Cancer Chemotherapy and Pharmacology|December 20, 2019
A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functionsNikki de Rouw, Sabine Visser, Stijn L W Koolen, et al.
AIDS (London, England)|June 17, 2005
Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modificationsCharles J L la Porte, Emile F Schippers, Marchina E van der Ende, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 27, 2011
Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice dailyReshmie A Ramautarsing, Jasper van der Lugt, Meena Gorowara, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2004
Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteersC J L la Porte, E P H Colbers, R Bertz, et al.
AIDS (London, England)|April 9, 2009
Clinical experience with the combined use of lopinavir/ritonavir and rifampicinRafaëlla Fa L'homme, Hanneke M J Nijland, Luuk Gras, et al.
Pageof 113

Showing results (781-790 of 1,123) with videos related to

Sort By:
Pageof 113
Antiviral Therapy|October 2, 2003
Administration of indinavir and low-dose ritonavir (800/100 mg twice daily) with food reduces nephrotoxic peak plasma levels of indinavirRob E Aarnoutse, Jan-Christian Wasmuth, Gerd Fätkenheuer, et al.
Der Urologe. Ausg. A|July 2, 2016
[What do prostate cancer patients know about smoking? : Results of a bicentric questionnaire study (KRAUT study)]M May, C Gilfrich, P Spachmann, et al.
Lung Cancer (Amsterdam, Netherlands)|March 20, 2019
Pharmacokinetically-guided dosing of pemetrexed in a patient with renal impairment and a patient requiring hemodialysisN de Rouw, S Croes, R Posthuma, et al.
Antiviral Therapy|February 7, 2009
Pharmacokinetics of lopinavir in HIV type-1-infected children taking the new tablet formulation once dailyMichiel van der Flier, Gwenda Verweel, Linda C van der Knaap, et al.
Atherosclerosis|August 10, 2024
Course of the effects of LDL-cholesterol reduction on cardiovascular risk over time: A meta-analysis of 60 randomized controlled trialsPascal M Burger, Jannick A N Dorresteijn, Stefan Koudstaal, et al.
Cancer Chemotherapy and Pharmacology|December 20, 2019
A limited sampling schedule to estimate individual pharmacokinetics of pemetrexed in patients with varying renal functionsNikki de Rouw, Sabine Visser, Stijn L W Koolen, et al.
AIDS (London, England)|June 17, 2005
Pharmacokinetics of once-daily lopinavir/ritonavir and the influence of dose modificationsCharles J L la Porte, Emile F Schippers, Marchina E van der Ende, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|October 27, 2011
Neither branded nor generic lopinavir/ritonavir produces adequate lopinavir concentrations at a reduced dose of 200/50 mg twice dailyReshmie A Ramautarsing, Jasper van der Lugt, Meena Gorowara, et al.
Antimicrobial Agents and Chemotherapy|April 24, 2004
Pharmacokinetics of adjusted-dose lopinavir-ritonavir combined with rifampin in healthy volunteersC J L la Porte, E P H Colbers, R Bertz, et al.
AIDS (London, England)|April 9, 2009
Clinical experience with the combined use of lopinavir/ritonavir and rifampicinRafaëlla Fa L'homme, Hanneke M J Nijland, Luuk Gras, et al.
Pageof 113